Obesity, Type 2 Diabetes
Conditions
Keywords
Calorie restriction, Type 2 diabetes, Obesity, Diabetic nephropathy prevention
Brief summary
The study investigates whether a long-term 25% caloric restriction can prevent onset and/or progression of renal function deterioration, retinal involvement and cardiovascular complications in overweight/obese type 2 diabetic patients, trough the amelioration of concomitant metabolic abnormalities such as visceral obesity, insulin resistance, dyslipidemia, hypertension and inflammation. The main aim of the study is therefore to evaluate the role of calorie restriction (CR) on subjects at risk of nephropathy. Secondary aims are to better understand the relationship between CR and the following aspects: renal disease and its associated metabolic abnormalities, retinopathy and cardiovascular complications, quality of life and treatment cost.
Interventions
BEHAVIORALCalorie restriction (25%)
BEHAVIORALAd libitum health diet
Sponsors
Istituto Superiore di Sanità
Mario Negri Institute for Pharmacological Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>40 years; * Type 2 diabetes (ADA criteria); * UAE \<300 mg/24h; * Body mass index (BMI)\>27kg/m2; * Serum creatinine \< 1.2 mg/dL; * No major changes in calorie, protein and sodium intake in the last 6 mos; * No major changes in concomitant treatments with blood pressure, glucose or lipid lowering agents since 6 and 3 months respectively; * Patients legally able to give written informed consent to the trial (signed and dated by the patient); * Written informed consent.
Exclusion criteria
* Concomitant non-diabetic renal disease or ischemic kidney disease; * Primary or immune-mediated renal disease; * Urinary tract obstruction or infection; * Treatment with steroids and/or non-steroid anti-inflammatory agents; * Treatment with thiazide or loop diuretics that, on the basis of the Investigator's judgment, might sustain hypovolemia and/or sodium depletion (with secondary kidney hypoperfusion/hypofiltration); * Hearth failure and/or hemodynamically significant left ventricular systolic dysfunction, cirrhosis, uncontrolled hyperglycemia resulting in glycosuria, hyper/hyponatremia of any cause; * Previous surgical procedures for weight loss; * Previous episodes of depression, or suicide attempts; * Chronic abuse of alcohol and drugs; * Pregnancy, ineffective contraception or peri-menopausal age; * Cancer or any chronic disease that might affect the completion of the study; * Chronic obstructive pulmonary disease (COPD) in treatment with positive airway pressure; * Unwillingness or inability to adhere to CR intervention over the entire 24-months intervention period; * Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial; * Evidence of an uncooperative attitude; * Any evidence that patient will not be able to complete the trial follow-up; * Inability to fully understand the potential risks and benefits of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end | At baseline, 6, 12 and 24 month |
Countries
Italy
Outcome results
None listed